| Keywords: |
treatment outcome; treatment response; treatment failure; gene mutation; overall survival; lenalidomide; prednisone; doxorubicin; cancer combination chemotherapy; gemcitabine; comparative study; phenotype; gene; progression free survival; gene expression; editorial; cyclophosphamide; vincristine; pathology; retrospective study; cancer therapy; peripheral t cell lymphoma; t cell lymphoma; epigenetics; janus kinase; rhoa guanine nucleotide binding protein; oxaliplatin; romidepsin; azacitidine; tet2 gene; belinostat; stat protein; dna methyltransferase 3a; post hoc analysis; phase 2 clinical trial (topic); phase 3 clinical trial (topic); lymphoma, t-cell, peripheral; hepatosplenic t cell lymphoma; anaplastic large cell lymphoma; multicenter study (topic); overall response rate; failure free survival; clonal hematopoiesis; long term survival; brentuximab vedotin; isocitrate dehydrogenase 2; ruxolitinib; humans; human; duvelisib; tumor necrosis factor receptor superfamily member 8; jak-stat signaling; tfh cell; cerdulatinib; valemetostat; adult t cell leukemia; golidocitinib; angioimmunoblastic type lymphoma; t-follicular helper cell lymphoma
|
